AI assistant
Sending…
RIGEL PHARMACEUTICALS INC — Director's Dealing 2017
Feb 7, 2017
32801_dirs_2017-02-06_c86dedee-152c-4c32-bc7f-8ff50e47e37f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RIGEL PHARMACEUTICALS INC (RIGL)
CIK: 0001034842
Period of Report: 2017-02-02
Reporting Person: Duliege Anne-Marie (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-02-02 | Stock Option (Right to Buy) | $2.11 | A | 150000 | Acquired | 2027-02-02 | Common Stock (150000) | Direct |
Footnotes
F1: The shares vest monthly over four (4) years from January 1, 2017.
More from RIGEL PHARMACEUTICALS INC
Regulatory Filings
2026
May 20
Proxy Solicitation & Information Statement
2026
Apr 3
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 3
Annual Report
2026
Mar 3
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 19